Next date
First Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan) · press release
Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- A cancer drug that hits three targets: two brakes on the immune system (PD-1 and CTLA-4) and VEGF, which feeds the tumour's blood vessels.PD-1/VEGF/CTLA-4 trispecific antibody
- How it’s given
- “CS2009 will be administered via intravenous (IV) infusion on Day 1 of repeated 14/21-day cycles (Q2W/Q3W).”In the company’s words, NCT06741644 on ClinicalTrials.gov
- Tested for
- Advanced Solid Tumors
- Main trialPhase 1/2
- “This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS2009 as Monotherapy and Combination Therapy in Participants with Advanced Solid Tumors. The study is comprised of a Phase I dose escalation and Phase II dose expansion.”In the company’s words, NCT06741644 on ClinicalTrials.gov
Coming up2
- DecFirst Phase 3 trials planned to start by end of 2026 (NSCLC, CRC, ES-SCLC; company plan) · press release
- Jan 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Jan 2027 | A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 16 Nov 2026 · EU trials register (CTIS) updated 16 Nov 2026 · openFDA updated 13 Nov 2026